Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis

Rheumatology (United Kingdom)

Volumn 53, Issue 2, 2014, Pages 233-239

  Chandran, Vinod ^a,b   Bull, Shelley B ^c,d   Pellett, Fawnda J ^a   Ayearst, Renise ^a   Pollock, Remy A ^a   Gladman, Dafna D ^a,b,e  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Genetic association; Innate immunity; Interaction; NK cell; Psoriasis

Indexed keywords

HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1;

ADULT; ALLELE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS;

GENETIC ASSOCIATION; INNATE IMMUNITY; INTERACTION; NK CELL; PSORIASIS;

ADULT; ALLELES; ARTHRITIS, PSORIATIC; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-C ANTIGENS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; RECEPTORS, KIR; RECEPTORS, KIR2DL2; REGRESSION ANALYSIS;

EID: 84892490717     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket296     Document Type: Article

References (28)

1. Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005;17:406-12.
2. Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009;11:214.
3. McQueen FM, Skinner MA, Krissansen GW et al. Natural killer cell function and expression of beta 7 integrin in psoriatic arthritis. J Rheumatol 1994;21:2266-73.
4. Spadaro A, Scrivo R, Moretti T et al. Natural killer cells and gamma/delta T cells in synovial fluid and in peripheral blood of patients with psoriatic arthritis. Clin Exp Rheumatol 2004;22:389-94.
5. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-74.
6. Carrington M, Norman P. The KIR gene cluster. National Library of Medicine (U.S.). Bethesda, MD, USA: National Center for Biotechnology Information, 2003. http://www. ncbi.nlm.nih.gov/entrez/query.fcgi?db=Books (18 July 2013, date last accessed).
7. Thomas R, Apps R, Qi Y et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009;41: 1290-4.
8. Kulkarni S, Savan R, Qi Y et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011;472:495-8.
9. Barnstable CJ, Snary D, Crumpton MJ et al. The structure and evolution of the HLA-Bw4 and Bw6 antigens. Tissue Antigens 1979;13:334-41.
10. Martin MP, Gao X, Lee JH et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002;31:429-34.
11. Cella M, Longo A, Ferrara GB et al. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994;180: 1235-42.
12. Kulkarni S, Martin MP, Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol 2008;20: 343-52.
13. Nelson GW, Martin MP, Gladman D et al. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Iglike receptor combinations in psoriatic arthritis. J Immunol 2004;173:4273-6.
14. Martin MP, Nelson G, Lee JH et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002;169:2818-22.
15. Williams F, Meenagh A, Sleator C et al. Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum Immunol 2005;66:836-41.
16. Chandran V, Bull SB, Pellett FJ, Ayearst R, Rahman P, Gladman DD. Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Hum Immunol 2013;74: 1333-8.
17. Ostensen M, Førre O. Modulation of human natural killer cell function by cytokines and rheumatic disease. Scand J Rheumatol Suppl 1988;76:183-8.
18. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008;9:495-502.
19. Momot T, Koch S, Hunzelmann N et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 2004;50:1561-5.
20. Salim PH, Jobim M, Bredemeier M et al. Killer cell immunoglobulin-like receptor (KIR) genes in systemic sclerosis. Clin Exp Immunol 2010;160:325-30.
21. Lowe DP, Cook MA, Bowman SJ et al. Association of killer cell immunoglobulin-like receptors with primary Sjogren's syndrome. Rheumatology 2009;48:359-62.
22. Toloza S, Pellett F, Chandran V et al. Association of killer cell immunoglobulin-like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patients with lupus. Lupus 2008;17:793-8.
23. Suzuki Y, Hamamoto Y, Ogasawara Y et al. Genetic polymorphisms of killer cell immunoglobulinlike receptors are associated with susceptibility to psoriasis vulgaris. J Invest Dermatol 2004;122:1133-6.
24. Luszczek W, Mańczak M, Cislo M et al. Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum Immunol 2004;65:758-66.
25. Lopez-Larrea C, Blanco-Gelaz MA, Torre-Alonso JC et al. Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations. Arthritis Res Ther 2006;8:R101.
26. Harvey D, Pointon JJ, Sleator C et al. Analysis of killer immunoglobulin-like receptor genes in ankylosing spondylitis. Ann Rheum Dis 2009;68:595-8.
27. Díaz-Peña R, Vidal-Castiñeira JR, Alonso-Arias R et al. Association of the KIR3DS1*013 and KIR3DL1*004 alleles with susceptibility to ankylosing spondylitis. Arthritis Rheum 2010;62:1000-6.
28. International HIV Controllers Study, Pereyra F, Jia X et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010;330: 1551-7.